Our Investments

Psych Capital includes the industry’s leading data and market intelligence platform(s).

Shortwave Pharma™

Drug Development

Shortwave Pharma works to address the unmet medical needs of patients suffering from treatment resistant mental health and chronic conditions, with a particular focus on eating disorders.


Media & Intelligence

PSYCH is a B2B media and intelligence platform for the psychedelic science and healthcare industry. It has quickly become the leading global resource for networking, insights and opportunities – powered by trustworthy data, independent analysis and engaging events that attract the largest B2B audience in the industry.



Awakn Life Sciences is a clinical biotech company researching, developing and delivering evidenced-based psychedelic medicine to treat addiction and other mental health conditions.


Data & Intelligence

Blossom is the leading source for scientific and regulatory data for the psychedelics industry. Blossom is presently collaborating with PSYCH to build the industry’s first SAAS platform.

You X Psych Capital

Are you a founder with a strong track record in science, healthcare or business looking for pre-seed capital or to incubate a company in psychedelic healthcare?